Announcement PDF ABN 16 165 160 841 +61 (0) 3 9123 1140 | info@ampliatx.com Level 5, 90 William Street, Melbourne VIC 3000 Australia www.ampliatx.com 28 AUGUST 2026 ASX RELEASE CEO & MANAGING DIRECTOR’S PRESENTATION TO ANNUAL GENERAL MEETING Melbourne, Australia: Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to release the CEO & Managing Director’s presentation to the Company’s Annual General Meeting (YE 31 March 2026) to be held today. This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics. Investor Contact: Dr Chris Burns Chief Executive Officer chris@ampliatx.com U.S. Contact: Robert Giordano rjgiordano@ggrouplifesciences.com +1 917 327 3938 Media Contact: H^CK Director, Haley Chartres haley@hck.digital +61 411 235 692 U.S. Media: media@ampliatx.com About Amplia Therapeutics Limited Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn. About Narmafotinib Narmafotinib (AMP945) is the company’s best-in-class inhibitor of FAK, a protein over-expressed in multiple cancers and a drug target gaining increasing attention for its role in solid tumours. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently being investigated in the ACCENT trial in advanced pancreatic cancer where it is dosed in combination with the chemotherapies gemcitabine and nab-paclitaxel (Abraxane® ) in first-line patients. The trial has achieved its desired outcome in achieving a response rate of 36%, superior to chemotherapy alone as reported for the benchmark MPACT study. A median Overall Survival (mOS) of 11.1 months has been reported along with an unprecedented complete response rate of 7.8%. A second trial (AMPLICITY) is being run at sites in Australia investigating the combination of narmafotinib with the chemotherapy mFOLFIRINOX in advanced pancreatic cancer patients, and a third trial in ovarian cancer (the PRROSE trial) is scheduled to begin recruiting later this year. 1 ampliatx.com | @ampliatx ASX: ATX | OTCQB: INNMF 2 8 A u g u s t 2 0 2 6 AGM Presentation Progress in the development of narmafotinib Dr Chris Burns CEO and MD 2 This presentation (Presentation) contains summary information about Amplia Therapeutics Limited ACN 165 160 841 and its subsidiaries (the Company or Amplia) which is current as at 30 June 2026. By attending an investor presentation or briefing, or accepting, accessing or reviewing this Presentation, you acknowledge and agree to the terms set out below. Summary Information: This Presentation has been prepared for information purposes only and is a summary only. It should be read in conjunction with Amplia’s most recent financial report and other periodic and continuous disclosure information lodged with the Australian Securities Exchange (ASX), which is available at www.asx.com.au. Subject only to any legal obligation to do so, the Company does not have any obligation to correct or update the content of this Presentation. Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past performance is not, and should not be relied on as being, indicative of future performance. Future performance and forward-looking statements: This Presentation includes forward looking statements, which can generally be identified by the use of words such as “may”, “will”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “outlook”, “forecast” and “guidance”, or other similar words. They may include, without limitation, statements regarding plans, strategies and objectives and anticipated business developments. Forward-looking statements inherently involve known and unknown risks, uncertainties and other factors that may cause Amplia’s actual results, performance and achievements to differ materially from statements in this Presentation. Forward-looking statements are based on the Company’s good faith assumptions as to the financial market, regulatory and other relevant environments that will exist and affect Amplia’s business and operations in the future. The Company does not give any assurance that the assumptions will prove to be correct. There may be other factors that could cause actual results or events not to be as anticipated, and many events are beyond the reasonable control of the Company. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements in this Presentation are only made as at the date of this Presentation and the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based. Industry data and third party information: Industry data and third party information used in this Presentation may have been obtained from research, surveys, reports or studies conducted by third parties, including industry or general publications. Neither Amplia not its representatives have independently verified any such market or industry data. Financial Information: This Presentation contains historical financial information based on the Company’s results for the 12 month period ending 30 June 2026 and management accounts to 30 June 2026. All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are due to rounding. Disclaimer: To the maximum extent permitted by law, Amplia and its officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any forward-looking statement. Disclaimer 6 Introduction Highlights and Strategy Development Highlights Outstanding results across a range of activities and therapeutic areas 4 Preclinical data illustrating narmafotinib’s efficacy in combination with chemotherapy and targeted drugs, in a range of cancer models including pancreatic, ovarian and lung cancer Clinical evidence in advanced pancreatic cancer trial in combination with chemotherapy: unprecedented complete response rate when combined with chemotherapy, and superiority to chemotherapy alone across all measures in ACCENT Trial, with favorable tolerability profile Registrational pathway being finalized - aligned with FDA* input - with first stage of 3-part pivotal study initiated Collaboration and supply agreement with Lilly expands commercial potential with study in NSCLC; ANZGOG† partnership explores clinical opportunity in ovarian cancer * Food and Drug Administration; † Australia New Zealand Gynaecology Oncology Group Development Strategy Building a robust dataset demonstrating narmafotinib’s benefit 5 What we have achieved Where we are currently What we are building towards Clinical Trials Demonstrating benefit in defined patient population Registrational trial aligned with regulators for potential product approval Preclinical studies Therapeutic efficacy with defined mechanism Trial Collaborations to expand clinical and commercial opportunity Product Licence to third party/ies for commercialization or Co-development 6 ACCENT Trial in pancreatic cancer Excellent tolerability and responses observed 7.8% Complete response rate Chemo alone (~0.2%) 70% Disease control rate Chemo alone - 50% 11.1 Median overall survival Chemo alone - 8.5 mos. months No Extra Burden Safety & tolerability Over chemo alone ACCENT Pancreatic Cancer Trial Narmafotinib + gemcitabine and Abraxane in first-line advanced pancreatic cancer months 7 Underway Details to be finalized Details to be finalized ACCENT registration pathway ACCENT Mini ACCENT Reg - P2b ACCENT Reg - P3 Daily dosing at two dose levels GnP combination 12 patients across 2 cohorts 3–4 Australian sites Safety, tolerability, PK + efficacy Biomarker + fibrosis endpoints Targeting completion First patient dosing October 2026 Safety and PK review complete Q1 27 Builds on ACCENT Mini data to compare the two daily dosing levels head-to-head to identify the optimal dose of narmafotinib ahead of the Phase 3 study Pivotal registrational study conducted with the dose selected from P2b Designed to support FDA submission for narmafotinib approval in pancreatic cancer A three-part registration pathway designed around FDA feedback Following Project Optimus principles1 8 1. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus. Building on promising preclinical studies and literature data PRROSE Trial in Ovarian Cancer TRIAL PARTNER ANZGOG Australia New Zealand Gynaecological Oncology Group is the peak national gynaecological cancer research organisation in Australia and New Zealand, and includes a cooperative trials network spanning major hospitals and leading clinicians across the region PRROSE Trial An investigator-initiated pilot study led by Dr Gwo Yaw Ho of Monash Health and Monash University, and sponsored and coordinated through ANZGOG 10 Combining narmafotinib with standard-of-care chemotherapy 14 kRAS Inhibitors An exciting new class of anti-cancer therapies - well suited for FAK inhibitor combination kRAS mutations prevalent in cancer Significant cancer driver in multiple cancers; multiple drugs in development 12 Chart: See Trends in Canc. 2025, 11, 91-116. kRAS mutations prevalent in cancer Significant cancer driver in multiple cancers; multiple drugs in development 13 Clinical studies demonstrating good activity but resistance and tolerability a significant issue1 60+ kRAS drugs now in clinical development2 Across pancreatic cancer, NSCLC, colorectal cancer and others “It is now generally accepted that the long-term effectiveness of KRAS inhibitors will not be achieved through mono-therapy, but rather through combination therapy.” Trends in Cancer 2025, 11, 91 Narmafotinib and kRAS inhibition Overcoming acquired resistance to kRAS inhibitors FAK signaling is an escape mechanism to blockade of RAS pathway1 Growing evidence for benefit of FAK + kRAS inhibition • Multiple preclinical studies, including Amplia’s own work, showing improved efficacy in combination2 • Clinical evidence recently published from small study in China3 14 1. Nat. Rev. Canc. 2021, 21, 313-324; 2. J. Thorac. Oncol. 2026, doi.org/10.1016/j.jtho.2026.103991; Adv. Sci. 2021, 2100250; 3. Lancet Respir. Med. 2026, doi.org/10.1016/S2213- 2600(26)00142-6 14 Lilly Collaboration kRAS G12C - FAK inhibitor combination Previously treated KRAS G12C-mutant advanced or metastatic NSCLC Phase 1b/2b study • Australian and US sites • Approx. 60 patients • Scheduled to start late 2026 Contractual • Amplia to sponsor and fund study using existing funds • Lilly to supply olomorasib in-kind for use in the study • Resulting data to be shared between both parties • Non-exclusive Lilly Collaboration Enhancing efficacy for next-generation kRAS G12C inhibitor olomorasib 16 Olomorasib - a next-generation kRAS G12C inhibitor1 • Improved potency and selectivity c/f approved drugs • Promising P1/2 data has supported further development • Currently undergoing two global Phase 3 studies in 1L NSCLC 1. Nature Comm. 2026, 17, 3834 2026 2027 2028 Estimated Development Timeline 2029 ACCENT ACCENT-mini ACCENT-reg PRROSE Olomorasib combination Potential second KRASi combination KRASi arm FDA Meeting FDA Meeting safety data 17 Amplia Therapeutics Limited ASX: ATX​ | OTCQB: INNMF info@ampliatx.com ampliatx.com Chris Burns CEO and MD chris@ampliatx.com​ PhD GAICD FAHMS